Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for postprandial hypotension in older adults
ACTRN12625000080426Phase 2Recruiting
- Sponsor
- University of Adelaide
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Postprandial hypotension (PPH) comparing Ozempic with Placebo (2 arms). Primary endpoints: Maximum fall in systolic blood pressure after glucose drink and Heart rate AUC0-120 min. Started Mar 2025; status: recruiting.
02
Drugs
03
Conditions
Postprandial hypotension (PPH)
Beyond the preview
Go deeper on ACTRN12625000080426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000080426.